Diabetes & Cardiometabolic Disease:
Overcoming a Southern Epidemic

Location: Memphis, TN
Date: December 5, 2012

Meeting Overview

Venue:
Memphis Marriott
Primary Audience:
Primary Care
Credits:
Refer to Accreditation Tab

Registration for this program is now closed. However, you can still register for Diabetes & Cardiometabolic Disease: Overcoming a Southern Epidemic in other southeast cities.

Register for the Southern Diabetes Initiative 

Despite advances in prevention, diagnosis, and treatment, diabetes and cardiometabolic disease have risen to epidemic proportions, particularly in the southeastern part of the United States. While challenging, it can be prevented and effectively managed.

Diabetes & Cardiometabolic Disease: Overcoming a Southern Epidemic, presented by Pri-Med, is a new, one-day continuing medical education program that will provide you unique, evidence-based performance improvement tools as well as case-based presentations and practical insights to help you improve patient outcomes. At this CME program, You’ll get answers to your most pertinent questions about:

  • Practical solutions for the control of hyperglycemia
  • How to advance therapies to achieve target goals
  • Insulin use in diabetes management
  • How to assess and manage cardiometabolic risk/disease
  • Translating novel and emerging therapies into better patient care

Admission is complimentary
Earn up to 8.75 AMA PRA Category 1 Credits™, 8.75 AANP contact hours, or 8.75 ACPE contact hours by attending this free CME meeting in Memphis.

Add to calendar

Have any ideas on how Pri-Med can improve your continuing medical education experience? Email us; we’d love to hear what you think.

*Centers for Disease Control and Prevention. National diabetes fact sheet: national estimates and general information on diabetes and prediabetes in the United States, 2011. Atlanta, GA: U.S. Department of Health and Human Services, Centers for Disease Control and Prevention, 2011.

Register Today

COURSE DIRECTOR
Course Director James Gavin III, MD, PhD
CEO/Chief Medical Officer
Healing Our Village, Inc.
Clinical Professor of Medicine
Emory University
School of Medicine
Atlanta, GA

Ensure that you remain on the front line of medical knowledge.
Never miss an update
Join our Mailing List »


Educational Grants

To date, the following organizations have provided educational grants in support of this Pri-Med activity: Abbott, Amylin Pharmaceuticals, Inc., Daiichi Sankyo, Inc., Novo Nordisk Inc., and Vivus.

Sessions & Syllabus

filler

Print Syllabus
View Schedule for:
Wednesday, December 05, 2012
7:00 AM-7:45 AM Registration & Continental Breakfast
7:45 AM-8:00 AM Opening Remarks
Keynote Address
8:00 AM-8:45 AM
Brent M. Egan, MD (Read Bio), Professor of Medicine & Pharmacology, Medical University of South Carolina, Charleston, SC, Senior Medical Director, Hypertension Initiative/OQUIN Network, Charleston, SC
8:45 AM-10:15 AM Practical Solutions for the Control of Hyperglycemia and Cardiometabolic Risk: What to Do After Lifestyle Intervention and Metformin

Learning Objectives:

  1. Assess the complex inter-relationships between insulin resistance and cardiometabolic disease, as well as acquire clinical strategies to educate patients on the value of diet, exercise and adherence to medications, in order to improve glycemic control and reduce cardiometabolic risk
  2. Implement and advance treatment strategies for patients not at glycemic target goals based on comparison of risks, benefits and utility of antihyperglycemic agents (including thiazolidinediones, DPP-4 inhibitors and GLP-1 agonists, as well as combination approaches) in affecting adherence and glycemic control
Frank Lavernia, MD, (Read Bio), Medical Founder and Director, North Broward Diabetes Center, Pompano Beach, FL, Private Practice, Coconut Creek, FL
10:15 AM-10:30 AM Networking Break
10:30 AM-12:00 PM Managing the Complexities of a Progressive Disease

Learning Objectives:

  1. Evaluate the mechanisms of action and risk-benefit profiles of emerging antihyperglycemic therapeutic strategies for the management of type 2 diabetes and confounding cardiometabolic risk
  2. Critically assess emerging clinical data on new investigational antihyperglycemic agents and the role they may play in better addressing unmet clinical needs of better managing glycemic profiles and accompanying comorbid complications
Lawrence Blonde, MD, FACP, FACE, (Read Bio), Director, Ochsner Diabetes Clinical Research Unit, New Orleans, LA, Department of Endocrinology, Diabetes and Metabolic Diseases, Ochsner Medical Center, New Orleans, LA
12:20 PM-1:50 PM Obesity and Type 2 Diabetes: Understanding the Benefits of Weight Loss in the Diabetic Population

Learning Objectives:

  1. Recognize the impact of excess weight on overall patient health and the risk for developing type 2 diabetes
  2. Identify patients with prediabetes and provide strategies to engage patients in open dialogues about the benefits of weight reduction, including diabetes prevention, highlighting the essential components of weight management and the importance of setting realistic weight loss goals
  3. Describe the expected benefits of life style change, structured weight loss programs, and pharmacologic agents on achieving weight reductions in the diabetic obese patient
  4. Effectively manage anti-diabetic medications and follow up care as a result of patient weight loss
Patrick O'Neil, PhD, (Read Bio), Director, Weight Management Center, Professor, Department of Psychiatry and Behavioral Sciences, Professor, Department of Surgery, Medical University of South Carolina, Charleston, SC, President, The Obesity Society, Charlston, SC
Nancy Bohannon, FACP, FACE, MD, (Read Bio), Director of Clinical Research, Cardiovascular Risk Reduction Program, St. Luke's Hospital, San Francisco, CA
2:00 PM-3:30 PM Insulin: Tried and True - Update on Best Practices in Clinical Use and Patient Adherence

Learning Objectives:

  1. Design strategies to help patients overcome cultural barriers to using insulin, and apply a team-based approach to initiating, switching and intensifying insulin therapies
  2. Employ the tenets of physiologic insulin replacement, and select between various insulin formulations to help patients meet individualized treatment target goal
Scott V. Joy, FACP, MD, (Read Bio), Associate Professor of Medicine, The University of Colorado Health System, Denver, CO, Medical Director, The Colorado Health Foundation, Denver, CO, Medical Director, The Colorado Health Foundation, Denver, CO
3:30 PM-3:45 PM Networking Break
3:45 PM-5:15 PM Managing Hypertension and Dyslipidemia in the Cardiometabolic Patient

Learning Objectives:

  1. Evaluate the cardiometabolic profiles of various antihyperglycemic agents to increase effective management of hypertension and dyslipidemias in patients with type 2 diabetes, with special attention to patients with impaired renal function
  2. Critically evaluate evidence-based strategies to mitigate CV risk in patients, including the risks and benefits of pharmacologic therapies for patients with pre-diabetes and mixed dyslipidemia
W. Timothy Garvey, MD, (Read Bio), Butterworth Professor and Chair, Department of Nutrition Sciences, GRECC Investigator and staff physician, Birmingham VA Medical Center, Director, UAB Diabetes Research and Training Center, University of Alabama at Birmingham, Birmingham, AL
5:15 PM-5:45 PM Closing Remarks: Value of Collaborative Care to Improve Quality

Learning Objectives:

  1. Assess and apply team-based, collaborative clinical approaches to better prevent and manage the progression of cardiometabolic risk and comorbid components, including diabetes, hypertension, dyslipidemia and obesity, so as to improve health outcomes in their patients
Brent M. Egan, MD, (Read Bio), Professor of Medicine & Pharmacology, Medical University of South Carolina, Charleston, SC, Senior Medical Director, Hypertension Initiative/OQUIN Network, Charleston, SC
W. Timothy Garvey, MD, (Read Bio), Butterworth Professor and Chair, Department of Nutrition Sciences, GRECC Investigator and staff physician, Birmingham VA Medical Center, Director, UAB Diabetes Research and Training Center, University of Alabama at Birmingham, Birmingham, AL

Accreditation

Credits Type Accreditation Statement Designation Statement
8.75 AMA PRA Category 1 Credits™ pmiCME is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. pmiCME designates this live educational activity for a maximum of 8.75 AMA PRA Category 1 Credits™. Physicians should only claim credit commensurate with the extent of their participation in the activity.
8.75 AAFP This live activity, Diabetes & Cardiometabolic Disease: Overcoming a Southern Epidemic, with a begin date of 12/5/2012-12/5/2012, has been reviewed and is acceptable for up to 8.75 Prescribed credit(s) by the American Academy of Family Physicians. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
8.75 AANP pmiCME is approved as a provider of nurse practitioner continuing education programs by the American Association of Nurse Practitioners. AANP Provider number 040308. This program has been approved for 8.75 contact hours of continuing education (which includes 4.375 hours of pharmacology).
8.75 ACPE
ACPE Logo
pmiCME is accredited by the accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. pmiCME designates this continuing education activity for 8.75 contact hours (.875 CEUs) of continuing pharmacy education.

Faculty

Brent Egan, MD (Read Bio)

Professor of Medicine & Pharmacology, Medical University of South Carolina, Charleston, SC
Senior Medical Director, Hypertension Initiative/OQUIN Network, Charleston, SC

Presenting on:

  • Keynote Address: The Role of Culturally Competent Medicine in Prevention, Diagnosis, and Management of Diabetes and Cardiometabolic Risk
    Wednesday, December 05, 2012, 8:00 AM-8:45 AM
  • Closing Remarks: Value of Collaborative Care to Improve Quality
    Wednesday, December 05, 2012, 5:15 PM-5:45 PM

Frank Lavernia, MD (Read Bio)

Medical Founder and Director, North Broward Diabetes Center, Pompano Beach, FL
Private Practice, Coconut Creek, FL

Presenting on:

  • Practical Solutions for the Control of Hyperglycemia and Cardiometabolic Risk: What to Do After Lifestyle Intervention and Metformin
    Wednesday, December 05, 2012, 8:45 AM-10:15 AM

Lawrence Blonde, MD, FACP, FACE (Read Bio)

Director, Ochsner Diabetes Clinical Research Unit, New Orleans, LA
Department of Endocrinology, Diabetes and Metabolic Diseases, Ochsner Medical Center, New Orleans, LA

Presenting on:

  • Managing the Complexities of a Progressive Disease
    Wednesday, December 05, 2012, 10:30 AM-12:00 PM

Patrick O'Neil, PhD (Read Bio)

Director, Weight Management Center, Professor, Department of Psychiatry and Behavioral Sciences, Professor, Department of Surgery, Medical University of South Carolina, Charleston, SC
President, The Obesity Society, Charlston, SC

Presenting on:

  • Obesity and Type 2 Diabetes: Understanding the Benefits of Weight Loss in the Diabetic Population
    Wednesday, December 05, 2012, 12:20 PM-1:50 PM

Nancy Bohannon, FACP, FACE, MD (Read Bio)

Director of Clinical Research, Cardiovascular Risk Reduction Program, St. Luke's Hospital, San Francisco, CA

Presenting on:

  • Obesity and Type 2 Diabetes: Understanding the Benefits of Weight Loss in the Diabetic Population
    Wednesday, December 05, 2012, 12:20 PM-1:50 PM

Scott Joy, FACP, MD (Read Bio)

Associate Professor of Medicine, The University of Colorado Health System, Denver, CO
Medical Director, The Colorado Health Foundation, Denver, CO
Medical Director, The Colorado Health Foundation, Denver, CO

Presenting on:

  • Insulin: Tried and True - Update on Best Practices in Clinical Use and Patient Adherence
    Wednesday, December 05, 2012, 2:00 PM-3:30 PM

W. Timothy Garvey, MD (Read Bio)

Butterworth Professor and Chair, Department of Nutrition Sciences, GRECC Investigator and staff physician, Birmingham VA Medical Center, Director, UAB Diabetes Research and Training Center, University of Alabama at Birmingham, Birmingham, AL

Presenting on:

  • Managing Hypertension and Dyslipidemia in the Cardiometabolic Patient
    Wednesday, December 05, 2012, 3:45 PM-5:15 PM
  • Closing Remarks: Value of Collaborative Care to Improve Quality
    Wednesday, December 05, 2012, 5:15 PM-5:45 PM
Start:  End: 
Expand Expand Instructions Print PrintMap

Travel Arrangements

Meeting Location

Memphis Marriott
2625 Thousand Oaks Boulevard
Memphis, TN 38118
(800)582-1601

Hotel Accommodations

A limited number of rooms have been reserved at the Memphis Marriott. Please call (800)582-1601 by 11/20/2012 and identify yourself as a Diabetes & Cardiometabolic Disease attendee to receive the discounted rate of $127.